Health1 min read

US FDA declines to approve Capricor's Duchenne treatment citing unreliable trial data; shares slump - Reuters

By · Published by Everything Blog

In short

The regulatory body formally rejected the application after finding the underlying clinical trial data to be unreliable. This negative decision directly hinders the company's planned market entry for the therapy. Following the announcement, investor confidence dropped rapidly, leading to a substantial decline in the company's share price.

Key points

  • Regulatory authorities determined that the submitted clinical trial information lacked su…: Regulatory authorities determined that the submitted clinical trial information lacked sufficient reliability for drug approval.
  • The adverse decision creates a substantial developmental setback for bringing the therapy…: The adverse decision creates a substantial developmental setback for bringing the therapy to the commercial market.
  • Market valuation for Capricor dropped significantly in response to the agency's formal pr…: Market valuation for Capricor dropped significantly in response to the agency's formal product rejection.

Sources checked by our analysis pipeline: 1

US FDA declines to approve Capricor's Duchenne treatment citing unreliable trial data; shares slump    Reuters

Health